Drugs / ARTS-011
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06260527 | Aug 2023 → Mar 2024 | — | Allorion Therapeutics Inc | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ARTS-011 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06260527 ↗ |
| Action | Inhibit | “acts as a small-molecule allosteric inhibitor of Tyk2” PMID 41730588 ↗ Feb 2026 |
| Modality | Small molecule | “acts as a small-molecule allosteric inhibitor of Tyk2” PMID 41730588 ↗ Feb 2026 |
| Route | Oral | “after single and multiple oral doses of ARTS-011” NCT06260527 ↗ |
| Target | TYK2 | “selectively targeting the JH2 domain of the Tyk2 protein.” PMID 41730588 ↗ Feb 2026 |